HCM
MCRB icon

Highbridge Capital Management’s Seres Therapeutics MCRB Stock Holding History

Highbridge Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,113
Closed -$252K – 1686
2017
Q2 		$252K Sell
1,113
-429
-28% -$88.1K ﹤0.01% 1023
2017
Q1 		$347K Buy
1,542
+786
+104% +$160K 0.01% 1079
2016
Q4 		$150K Sell
756
-362
-32% -$78.9K ﹤0.01% 1173
2016
Q3 		$275K Buy
+1,118
New +$392K ﹤0.01% 1048

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Highbridge Capital Management's MCRB Position: Q3 2017 in Review

Highbridge Capital Management sold out of Seres Therapeutics (MCRB) in Q3 2017, closing a stake of 1,113 shares — an estimated $252K sold.

Highbridge Capital Management first reported a position in MCRB in Q3 2016 and held it in 4 quarters. The position peaked at $347K in Q1 2017. 80 funds tracked by Wall St. Rank hold MCRB as of Q3 2017.

  • Highbridge Capital Management reported no remaining Seres Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 1,113 Seres Therapeutics shares in Q3 2017, an estimated $252K.
  • Highbridge Capital Management first reported a position in Seres Therapeutics in Q3 2016 and held it in 4 quarters.
  • Highbridge Capital Management's Seres Therapeutics position peaked at $347K in Q1 2017.
  • 80 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.